The Filing Desk

Celldex Therapeutics vs CRISPR Therapeutics

Celldex Therapeutics CLDX · CRISPR Therapeutics CRSP · Biotechnology

CRISPR Therapeutics reported revenue of $4 million in fiscal 2025, 2.3 times Celldex Therapeutics' $2 million in fiscal 2025. Celldex Therapeutics' revenue fell 78.0% in its latest year, and CRISPR Therapeutics' fell 90.6%. Celldex Therapeutics had an operating margin of -18599.8%, against -18933.7% at CRISPR Therapeutics. Free cash flow was −$214 million at Celldex Therapeutics and −$346 million at CRISPR Therapeutics.

Side by side

Celldex TherapeuticsCRISPR Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$2M$4M
Revenue growth−78.0%−90.6%
Revenue growth a year, last 5 years−27.3%38.0%
Gross margin87.1%—
Operating margin−18,599.8%−18,933.7%
Net margin−16,748.0%−16,569.8%
Free cash flow−$214M−$346M
Free cash flow margin−13,829.1%−9,855.5%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count3.1%6.6%
Last close$28.83$42.24
P/E at the last close——
Insider trades, last 12 monthssold $121,231sold $14.5 million
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Celldex TherapeuticsCRISPR Therapeutics
Operating margin
Percent of revenue
Celldex TherapeuticsCRISPR Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Celldex TherapeuticsCRISPR Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Celldex Therapeutics and CRISPR Therapeutics pages.